Previous 10 | Next 10 |
Oncternal Therapeutics (ONCT) announces updated interim clinical data from the ongoing Phase 1/2 CIRLL clinical trial. "The interim data from the combination of cirmtuzumab and ibrutinib are quite promising in relapsed/refractory (r/r) MCL, with an impressive 87% best ORR that has improv...
Best objective response rate of 87% reported for 15 patients with relapsed/refractory mantle cell lymphoma, with a median follow-up of 12.1 months. Median progression-free survival (PFS) was not reached The combination of c irmtuzumab and ibrutinib has been wel...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks ended lower on Friday on raised concerns over the economic impact of the pandemic and the Treasury Department's new curtailing of emergency economic...
Gainers: Phoenix Tree (DNK) +91%.Naked Brand (NAKD) +64%.Kazia Therapeutics (KZIA) +32%.Micro Focus International (MFGP) +32%.BELLUS Health (BLU) +31%.InnSuites Hospitality Trust (IHT) +27%.FuelCell Energy (FCEL) +27%.Ashford Hospitality Trust (AHT) +24%.CIIG Merger (CIIC) ...
Oncternal Therapeutics (ONCT) -26% after raising 'bought deal' offering to $22.5M.PaySign (PAYS) -25% on Q3 earnings release.Interpace Biosciences (IDXG) -17%.New Concept Energy (GBR) -12%.Alterity Therapeutics (ATHE) -11%.Yunhong CTI (CTIB) -8%.Lowe's Companies (LOW)-6%...
Due to demand, Oncternal Therapeutics (ONCT) announces that the underwriter has agreed to increase the size of the previous public offering of ~7.3M common shares (from ~6.5M), to be priced at $3.10/share, for expected gross proceeds of ~$22.5M. Underwriter's over-allotment is an additional ~...
SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to demand, the underwriter has agreed to increase the size of the previously ...
SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC...
Gainers: Akers Biosciences (AKER) +45%, Cidara Therapeutics (CDTX) +29%, Five Prime Therapeutics (FPRX) +24%, Zhongchao (ZCMD) +22%, Vaxart (VXRT) +22%.Losers: Applied Therapeutics (APLT) -12%, Soliton (SOLY) -13%, Harmony ...
Interim Phase 1 data in patients with relapsed/refractory Ewing sarcoma treated at the recommended Phase 2 dose of TK216 demonstrated two durable complete responses, with no relapses after complete response SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) --...
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NASDAQ Market:
Oncternal Therapeutics Inc. Website:
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2024 financial results after the U.S. financial markets c...
2024-07-26 13:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its Pha...